Astrana Health (NASDAQ:ASTH) Shares Gap Up Following Better-Than-Expected Earnings

Astrana Health, Inc. (NASDAQ:ASTH)’s stock price gapped up prior to trading on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $20.33, but opened at $24.04. Astrana Health shares last traded at $26.3050, with a volume of 223,213 shares trading hands.

The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.39. The business had revenue of $950.53 million during the quarter, compared to the consensus estimate of $930.46 million. Astrana Health had a net margin of 0.71% and a return on equity of 5.63%. The business’s revenue was up 42.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.15) EPS.

Astrana Health News Summary

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Q4 results beat expectations: Astrana reported strong revenue growth (revenue ~$950.5M, +42.9% y/y) and reported EPS above consensus, a key fundamental positive that initially drove buying interest. Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Market reaction to the print and guidance was initially upbeat: coverage noted the stock rose after the results and management’s outlook. That short-term momentum can support near-term buying interest. Astrana Health stock rises above 3% on earnings beat and strong guidance
• Neutral Sentiment: Management will speak at investor conferences (TD Cowen fireside chat), improving visibility with institutional investors but not an immediate earnings driver. Astrana Health, Inc. to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Revenue guidance provided (FY revenue range ~ $3.8B–$4.1B; Q1 revenue range ~$900M–$1.0B) — the ranges roughly bracket consensus but are wide, leaving room for interpretation and volatility as analysts refine models.
• Neutral Sentiment: Short-interest reporting appears anomalous (entries showing 0 shares / NaN changes and 0.0 days to cover), suggesting data noise rather than a material short-squeeze signal; ignore until clearer updates.
• Negative Sentiment: Conflicting earnings-call transcripts (some reports show a smaller EPS/miss) have circulated, creating investor confusion and likely short-term selling/volatility despite the company’s official release. Astrana Health, Inc. Q4 2025 Earnings Call Transcript

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Zacks Research cut Astrana Health from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 10th. TD Cowen decreased their target price on Astrana Health from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Needham & Company LLC initiated coverage on Astrana Health in a research report on Friday, December 12th. They issued a “buy” rating and a $28.00 price target for the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrana Health in a research note on Tuesday, November 25th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Astrana Health in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Astrana Health presently has a consensus rating of “Hold” and an average price target of $35.33.

Institutional Trading of Astrana Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. boosted its stake in shares of Astrana Health by 46.0% during the fourth quarter. Invesco Ltd. now owns 355,216 shares of the company’s stock valued at $8,813,000 after acquiring an additional 111,980 shares during the last quarter. VARCOV Co. purchased a new position in Astrana Health in the 4th quarter valued at about $744,000. Wellington Management Group LLP boosted its stake in shares of Astrana Health by 418.3% during the 4th quarter. Wellington Management Group LLP now owns 738,853 shares of the company’s stock worth $18,331,000 after purchasing an additional 596,293 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Astrana Health during the fourth quarter worth about $334,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Astrana Health during the fourth quarter worth about $2,829,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Trading Down 6.9%

The company has a debt-to-equity ratio of 1.27, a current ratio of 1.40 and a quick ratio of 1.40. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of 53.28, a price-to-earnings-growth ratio of 0.78 and a beta of 0.91. The business’s 50-day moving average price is $23.56 and its two-hundred day moving average price is $26.24.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.